{"schema_version":"1","generated_at":"2026-11-09T08:28:14.626Z","data_as_of":null,"url":"https://www.findmykol.com/kol/gulrayz-ahmed","json_url":"https://www.findmykol.com/kol/gulrayz-ahmed/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"gulrayz-ahmed","name":"Gulrayz Ahmed","credential":"MD","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"city":"Milwaukee","state":"WI","region":{"label":"Midwest","url":"https://www.findmykol.com/region/midwest"}},"identifiers":{"npi":"1033561808","orcid":"0000-0001-6873-9571","openalex":"A5030283354"},"summary":"Gulrayz Ahmed is an Oncology physician. OpenAlex indexes 64 publications with 528 citations (h-index 12).","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":64,"cited_by_count":528,"h_index":12,"latest_activity_year":2026,"source":"works"},"payments":{"company_count":11,"program_years":{"first":2021,"last":null},"rows_total":17,"shown":3,"withheld":14,"rows":[{"payer":"AstraZeneca Pharmaceuticals LP","program_year":2025,"amount_usd":1184.33,"payment_count":2,"source_url":"https://openpaymentsdata.cms.gov/search?query=1033561808"},{"payer":"GENZYME CORPORATION","program_year":2025,"amount_usd":125,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1033561808"},{"payer":"Geron Corporation","program_year":2025,"amount_usd":123.12,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1033561808"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1033561808","source":"payments"},"prescribing":{"data_year":2024,"areas_total":1,"areas_shown":1,"areas":[{"area":"Dermatology","share_pct":100,"classes_total":1,"classes":[{"class":"Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor","setting":"prescribed","share_pct":100,"drugs":[{"name":"Acyclovir","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"facility","data_year":2022,"office_pct":0,"facility_pct":100},"source":"medicare"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Outcomes of CD20 Bispecific Antibodies after CD19 CAR T-cell Therapy in mantle cell lymphoma: A Multicenter Analysis from the Collaborative U.S. Bispecific Consortium (CUBIC)","year":2026,"journal":"Transplantation and Cellular Therapy","source_url":"https://doi.org/10.1016/j.jtct.2025.12.541","status":"verified"},{"title":"Outcomes of Hematopoietic Cell Transplantation in Patients with Plasmablastic Lymphoma","year":2026,"journal":"Transplantation and Cellular Therapy","source_url":"https://doi.org/10.1016/j.jtct.2026.05.030","status":"verified"},{"title":"Outpatient Versus Inpatient Management of Grade 1 Cytokine Release Syndrome in Follicular Lymphoma Patients Receiving Bispecific Antibodies: A Cubic Study","year":2026,"journal":"Transplantation and Cellular Therapy","source_url":"https://doi.org/10.1016/j.jtct.2025.12.678","status":"verified"},{"title":"Incidence of Pure Red Cell Aplasia Post Allogenic Hematopoietic Stem Cell Transplant in Patients with Major ABO Mismatch in Post Cytoxan Era — a Single Center Analysis","year":2026,"journal":"Transplantation and Cellular Therapy","source_url":"https://doi.org/10.1016/j.jtct.2025.12.684","status":"verified"},{"title":"Dual Targeted Lentiviral Transduced Anti-CD20/Anti-CD19 (LV20.19) CAR T cells for Relapsed, Refractory CLL","year":2026,"journal":"Transplantation and Cellular Therapy","source_url":"https://doi.org/10.1016/j.jtct.2025.12.098","status":"verified"}],"source":"works"},"contact":{"address_1":"9200 W WISCONSIN AVE","city":"Milwaukee","state":"WI","zip":"532263522","phone":"414-805-4600","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1033561808","source":"identity"},"similar":[{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Beth Karlan","slug":"beth-karlan","institution":"University of California, Los Angeles","specialty":"Gynecologic Oncology","url":"https://www.findmykol.com/kol/beth-karlan","json_url":"https://www.findmykol.com/kol/beth-karlan/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":14,"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2025-05-15","provider_certified":"2025-05-15","collected_at":"2026-11-06T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024}},"methodology_url":"https://www.findmykol.com/about#methodology"}